Baillie Gifford & CO Dexcom Inc Transaction History
Baillie Gifford & CO
- $127 Billion
- Q4 2024
A detailed history of Baillie Gifford & CO transactions in Dexcom Inc stock. As of the latest transaction made, Baillie Gifford & CO holds 14,612,792 shares of DXCM stock, worth $1.29 Billion. This represents 0.9% of its overall portfolio holdings.
Number of Shares
14,612,792
Previous 15,017,666
2.7%
Holding current value
$1.29 Billion
Previous $1.01 Billion
12.91%
% of portfolio
0.9%
Previous 0.77%
Shares
31 transactions
Others Institutions Holding DXCM
# of Institutions
1,043Shares Held
356MCall Options Held
5.32MPut Options Held
5.65M-
Vanguard Group Inc Valley Forge, PA47.4MShares$4.19 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY34.5MShares$3.05 Billion0.09% of portfolio
-
Capital Research Global Investors Los Angeles, CA17.9MShares$1.58 Billion0.26% of portfolio
-
State Street Corp Boston, MA16.7MShares$1.47 Billion0.05% of portfolio
-
Sands Capital Management, LLC Arlington, VA10.3MShares$911 Million2.2% of portfolio
About DEXCOM INC
- Ticker DXCM
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 386,257,984
- Market Cap $34.1B
- Description
- DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...